BioMed Realty (the “Company”), a Blackstone portfolio company and the largest private operator of life science real estate, announced today officer pr ...
NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.
BioMed Realty purchased a trio of Kendall Square buildings last week, adding to its spate of recent acquisitions in the lab ...
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for ...
Barclays initiated coverage of Orchestra BioMed (OBIO) with an Overweight rating and $16 price target The firm sees a “series of catalysts” ...
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
Anaconda Biomed S.L. announced that it named Trent Reutiman its new CEO. The company’s previous CEO Francois Salmon will n ...
Hosted on MSN6d
Barclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight RecommendationFintel reports that on January 2, 2025, Barclays initiated coverage of Orchestra BioMed Holdings (NasdaqGM:OBIO) with a Overweight recommendation. Analyst Price Forecast Suggests 174.91% Upside As of ...
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has progressed beyond the previously-announced non ...
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed” or the "Company") today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback